Recent Updates
Recently added Catalysts

NNC1679-0001

Phase 1

Healthy Volunteers | Small molecule | Metabolic |Novo Nordisk A/S|Last Updated: Jun 22, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment58

FDA Designations

No designations recorded

Clinical trial landscape

NNC1679-0001 · 1 trial · 2 indications

Phase 1 1
NCT07570992A Research Study to Evaluate the Safety of NNC1679-0001 When Given to Healthy Participants and Participants With T2DMHealthy Volunteers
RECRUITING58 Analytics
PHASE1RECRUITING
A Research Study to Evaluate the Safety of NNC1679-0001 When Given to Healthy Participants and Participants With T2DM
Healthy Volunteers
NCT0757099258
Unlock trial analytics

Study Endpoints

Primary Endpoints

Number of Treatment-Emergency Adverse Events (TEAEs)
From dosing (day 1) upto week 34

Measured in events.

Secondary Endpoints

Number of TEAEs
From dosing (day 1) until V15a/V15b (week 26)
Number of hypoglycaemic episodes
From dosing (day 1) upto week 34
AUC: The area under the NNC1679-0001 plasma concentration-time curve from time zero to the last measurable concentration after a single dose
From dosing (day 1) upto day 3 or day 15
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
NNC1679-0001EXPERIMENTALParticipants will receive NNC1679-0001 subcutaneously.
PlaceboPLACEBO_COMPARATORParticipants will receive placebo matched to NNC1679-0001 s.c.

Interventions

NameTypeDescription
NNC1679-0001DRUGNNC1679-0001 will be administered subcutaneously.
PlaceboDRUGPlacebo will be administered subcutaneously.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 64 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: All participants * Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine eligibility for the study. * Male or female (sex at birth) of nonchildbeari...

Countries:Austria
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

HIGHJun 22, 2026NCT07570992Enrollment: 80 → 58
HIGHJun 22, 2026NCT07570992Enrollment: 80 → 58

Frequently asked questions about NNC1679-0001

What is NNC1679-0001 used for?

NNC1679-0001 is an investigational small molecule being developed by Novo Nordisk for metabolic conditions. It is currently in a Phase 1 clinical trial evaluating its safety in healthy volunteers and participants with type 2 diabetes mellitus. The drug is not yet approved and remains in clinical development.

Who makes NNC1679-0001?

NNC1679-0001 is being developed by Novo Nordisk A/S, a pharmaceutical company listed on the stock exchange under the ticker NVO. The company is conducting a Phase 1 trial to evaluate the safety of this investigational small molecule in healthy participants and those with type 2 diabetes.

What phase is NNC1679-0001 in?

NNC1679-0001 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The ongoing Phase 1 trial is recruiting participants to assess the safety of the drug in healthy volunteers and individuals with type 2 diabetes mellitus.

What clinical trials is NNC1679-0001 in?

NNC1679-0001 is being studied in one active Phase 1 clinical trial with the identifier NCT07570992. This randomized, double-blind, placebo-controlled study is evaluating the safety of NNC1679-0001 in healthy participants and participants with type 2 diabetes mellitus. The trial is recruiting in Austria and aims to enroll 58 participants.

Is NNC1679-0001 being tested in healthy volunteers?

Yes, NNC1679-0001 is being tested in healthy volunteers. The Phase 1 clinical trial NCT07570992 is specifically designed to evaluate the safety of the drug in healthy participants as well as in participants with type 2 diabetes mellitus. The study is recruiting in Austria and is placebo-controlled.